180 Markets is turning the ASX around to make it fairer and easier for you to access capital raises. Our goal is to give investors the same access to capital raises as the world’s biggest fund managers. No more advantaged information or being the last person in. But it gets even better. You have true ownership of your shares, you…

As a massive class action builds over concussion in the AFL, another problem is emerging. Heavy knocks are causing injuries that leave players suffering from a lifetime of crippling chronic pain. Medicinal cannabis trial could help retired AFL players manage chronic pain

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) is one of three companies set to present at Proactive’s medical cannabis focussed webinar on Tuesday, August 11, along with MGC Pharmaceuticals Ltd (ASX:MXC) and Southern Cannabis Holdings. The Proactive CEO Investor Sessions is an online variant of the popular conference format the media company has run for over a decade and enables communication between…

Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCMKTS:ZLDAF) final clinical report for a Phase 1 dose escalation trial in chronic pain patients on long-term high-dose opioid treatment shows that the primary and secondary endpoints for safety and efficacy were met. Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints

Zelira Therapeutics (ASX:ZLD) has completed another medicinal cannabis trial and passed with flying colours. This time it was a Phase 1 dose escalation study assessing the safety of its cannabis formulation in chronic pain patients using opioids as a treatment. The study met its primary end points in being well tolerated and having no serious adverse effects. Pot stock Zelira…

Q&A with Osagie Imasogie  Chairman, Zelira Therapeutics Zelira Therapeutics Ltd (Zelira; the Company) is a leading global therapeutic medicinal cannabis company with access to the world’s largest and fastest growing cannabis markets. The Company is focused on developing clinically validated branded cannabis products for the treatment of a variety of medical conditions. Product development programs are underway targeting specific conditions…

Zelira says its 23-patient, phase Ib/IIa trial of marijuana-derived ZLT-101 has shown safety and statistical significance for reduction of chronic insomnia. Zelira said that the randomised, double-blind, cross-over trial treated patients for 14 nights with ZTL-101 and 14 nights of placebo, separated by a one-week washout period at the University of Western Australia Centre for Sleep Science. Biotech Daily –…

Zelira Therapeutics (ASX:ZLD) chief Dr Richard Hopkins confirms what your columnist suspected was a self-serving myth perpetuated by overzealous users of the intoxicating herb: no one has ever been recorded as overdosing on cannabis over millennia of usage. “The safety profile is amazing and that’s the bit that everyone has forgotten,” Dr Hopkins says. Stockhead – Dr Boreham’s Crucible: Zelira’s…

CFN Media Interviews Zelda Therapeutics at New West Summit

Forbes Article – Mara Gordon: Aunt Zelda’s, For Every Household